AAAAI Annual Meeting

Celltrion Biosimilar Demonstrates Equivalence With Xolair in Phase 1 Study

March 14th 2022

A phase 1 study testing Celltrion Healthcare’s omalizumab biosimilar in healthy subjects showed similar safety and pharmacokinetic profiles to the reference product (Xolair), as presented at the American Academy of Allergy Asthma and Immunology’s annual meeting.

Omalizumab Biologic is Changing the Face of Asthma Therapeutics

March 20th 2017

Dupilumab Improves Signs and Symptoms of Atopic Dermatitis Without Safety Issues

March 16th 2017

Fewer AEs With Humanized Antibody Treatments Favorable for Biosimilar Development

March 15th 2017

Case Study Indicates IVIG May Counteract Adalimumab

March 14th 2017

Dexpramipexole Lowers Blood and Tissue Eosinophils Without Severe Adverse Reactions

March 14th 2017